Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN III 10 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN III 10 versus LIQREV.
LIPOSYN III 10% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Liposyn III 10% is an intravenous fat emulsion that provides essential fatty acids (linoleic and linolenic acids) and a source of calories. The triglycerides are hydrolyzed by lipoprotein lipase to free fatty acids and glycerol, which are then utilized for energy production or stored. The emulsion particles are metabolized similarly to endogenous chylomicrons.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intravenous infusion: 500 mL to 1000 mL per day, providing 10% lipid emulsion (100 g fat per liter), infused over 8-12 hours as part of parenteral nutrition, not to exceed 2.5 g fat/kg/day.
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
Triglycerides in Liposyn III 10% have a terminal elimination half-life of approximately 0.5 to 1 hour in patients with normal lipid metabolism. In neonates or hepatic impairment, half-life may be prolonged.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Lipids are metabolized via hydrolysis by lipoprotein lipase into free fatty acids and glycerol. Free fatty acids undergo beta-oxidation or re-esterification. Elimination of CO2 via lungs; less than 5% excreted renally as glycerol and other metabolites.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion